FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy

FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy

Source: 
Pharmaforum
snippet: 

Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson’s disease which is currently in early-stage clinical testing.